company background image
1349

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd SEHK:1349 Stock Report

Last Price

HK$3.45

Market Cap

HK$8.5b

7D

-0.9%

1Y

-10.2%

Updated

29 Jan, 2023

Data

Company Financials

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

SEHK:1349 Stock Report

Mkt Cap: HK$8.5b

1349 Stock Overview

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products.

1349 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends2/6

My Notes

New

Notes are coming soon

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd
Historical stock prices
Current Share PriceHK$3.45
52 Week HighHK$4.02
52 Week LowHK$2.51
Beta0.43
1 Month Change-0.58%
3 Month Change33.72%
1 Year Change-10.16%
3 Year Change-23.84%
5 Year Change-10.62%
Change since IPO331.25%

Recent News & Updates

Recent updates

What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

Apr 12
What To Know Before Buying Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) For Its Dividend

We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Mar 22
We Think Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Can Manage Its Debt With Ease

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Mar 07
Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Feb 20
Are Strong Financial Prospects The Force That Is Driving The Momentum In Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s HKG:1349) Stock?

Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Feb 07
Could The Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Ownership Structure Tell Us Something Useful?

Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Jan 25
Should Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Be Disappointed With Their 38% Profit?

Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Jan 12
Should You Rely On Shanghai Fudan-Zhangjiang Bio-Pharmaceutical's (HKG:1349) Earnings Growth?

Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Dec 28
Would Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKG:1349) Be Valuable To Income Investors?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Dec 15
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) Seems To Use Debt Rather Sparingly

Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Dec 03
Should You Be Adding Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) To Your Watchlist Today?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 21
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.'s (HKG:1349) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Shareholder Returns

1349HK PharmaceuticalsHK Market
7D-0.9%1.6%2.7%
1Y-10.2%3.4%-6.2%

Return vs Industry: 1349 underperformed the Hong Kong Pharmaceuticals industry which returned 3.4% over the past year.

Return vs Market: 1349 underperformed the Hong Kong Market which returned -6.2% over the past year.

Price Volatility

Is 1349's price volatile compared to industry and market?
1349 volatility
1349 Average Weekly Movement4.7%
Pharmaceuticals Industry Average Movement8.2%
Market Average Movement7.8%
10% most volatile stocks in HK Market15.6%
10% least volatile stocks in HK Market3.9%

Stable Share Price: 1349 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 1349's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996817Hai Bo Wanghttps://www.fd-zj.com

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary

How do Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's earnings and revenue compare to its market cap?
1349 fundamental statistics
Market CapHK$8.54b
Earnings (TTM)HK$151.77m
Revenue (TTM)HK$1.34b

23.4x

P/E Ratio

2.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1349 income statement (TTM)
RevenueCN¥1.16b
Cost of RevenueCN¥87.05m
Gross ProfitCN¥1.07b
Other ExpensesCN¥939.91m
EarningsCN¥131.51m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.13
Gross Margin92.49%
Net Profit Margin11.35%
Debt/Equity Ratio0%

How did 1349 perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

49%

Payout Ratio